Combination Ceftolozane-Tazobactam for Complicated Urinary Tract Infections

In a multinational, randomized, double-blind trial involving patients with complicated urinary tract infections or pyelonephritis, treatment response was better with ceftolozane-tazobactam than with high-dose levofloxacin.

The increasing resistance of uropathogens to fluoroquinolones has limited the options for treating urinary-tract infections. In an industry-supported, phase III, double-blind, double-dummy trial conducted at 209 centers in 25 countries, investigators randomized hospitalized adults with a diagnosis of complicated lower urinary tract infection or pyelonephritis to receive 7 days of ceftolozane-tazobactam (1.5 g intravenously every 8 hours) or levofloxacin (750 mg intravenously once daily). Patients with severe renal failure were excluded. Dosage in other patients was adjusted based on creatinine clearance. Treatment was modified after enrollment in patients found to have infection resistant to the drug they were receiving.

Among the 800 partic…

Reviewing Author

Mary E. Wilson, MD

Disclosures

Consultant/Advisory BoardOneHealthTrust (formerly Center for Disease Dynamics, Economics, and Policy); Global Health Institute, University of Wisconsin

RoyaltiesUpToDate

Editorial BoardsJournal of Travel Medicine

Mary E. Wilson, MD

Disclosures

Consultant/Advisory BoardOneHealthTrust (formerly Center for Disease Dynamics, Economics, and Policy); Global Health Institute, University of Wisconsin

RoyaltiesUpToDate

Editorial BoardsJournal of Travel Medicine

Combination Ceftolozane-Tazobactam for Complicated Urinary Tract Infections

Topics

Reviewing Author